Fortrea Holdings (FTRE) Total Non-Current Liabilities (2022 - 2026)

Fortrea Holdings (FTRE) posted Total Non-Current Liabilities of $2.1 billion for Q1 2026, little changed on a QoQ basis from $2.1 billion in Q4 2025, and down 4.78% year-over-year from $2.2 billion in Q1 2025.

Fortrea Holdings (FTRE) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends

Fortrea Holdings' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $2.1 billion for Q1 2026.

  • Quarterly Total Non-Current Liabilities fell 4.78% year-over-year to $2.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 billion (down 4.78% YoY) and the FY2025 annual result came in at $2.1 billion, down 3.14% from the prior year.
  • Total Non-Current Liabilities was $2.1 billion for Q1 2026 at Fortrea Holdings, roughly flat from $2.1 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $2.6 billion in Q1 2024 and bottomed at $923.6 million in Q4 2022.
  • A 5-year average of $2.2 billion and a median of $2.2 billion in 2024 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 180.03% — and 2024, when it fell 19.21%.
  • Fortrea Holdings' Total Non-Current Liabilities stood at $923.6 million in 2022, then soared by 180.03% to $2.6 billion in 2023, then declined by 15.65% to $2.2 billion in 2024, then declined by 3.14% to $2.1 billion in 2025, then rose by 0.32% to $2.1 billion in 2026.
  • Business Quant data shows FTRE's Total Non-Current Liabilities at $2.1 billion in Q1 2026, $2.1 billion in Q4 2025, and $2.1 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Fortrea Holdings 1.83 Bn 1.68 Bn 123.60 Mn 2.12 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 2.12 Bn
Dec 31, 2025 2.11 Bn
Sep 30, 2025 2.12 Bn
Jun 30, 2025 2.21 Bn
Mar 31, 2025 2.23 Bn
Dec 31, 2024 2.18 Bn
Sep 30, 2024 2.11 Bn
Jun 30, 2024 2.07 Bn
Mar 31, 2024 2.62 Bn
Dec 31, 2023 2.59 Bn
Sep 30, 2023 2.59 Bn
Jun 30, 2023 2.57 Bn
Dec 31, 2022 923.60 Mn